Periolimel 2.5% E 0.06 g (l-Tyrosine EMULSION) 0.06 G

Periolimel 2.5% E 0.06 G is an intravenous emulsion containing L-Tyrosine, an amino acid used for nutritional support. This product is manufactured by Baxter Corporation in Canada and is available in various pack sizes.

Strength

0.06 G

Pack Size

1000/1500/2000/2500ML

Manufacturer / TM Owner

BAXTER CORPORATION

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Periolimel 2.5% E 0.06 G is primarily used for nutritional support in patients who require intravenous administration of L-Tyrosine. This amino acid is essential for the synthesis of proteins and other important molecules in the body. It is often used in clinical settings to support patients who cannot obtain adequate nutrition through oral intake.

Side Effects

The effects of Periolimel 2.5% E 0.06 G can vary depending on individual patient needs. L-Tyrosine is generally well-tolerated, but some patients may experience mild side effects such as nausea or vomiting. It is important to monitor patients closely for any adverse reactions.

Precautions & Warnings

Periolimel 2.5% E 0.06 G should be handled with care to ensure proper administration. It is crucial to follow the manufacturer's guidelines for storage and preparation. Patients with known allergies to L-Tyrosine or any of the ingredients should avoid using this product.

Avoid Interactions

L-Tyrosine can interact with certain medications, including monoamine oxidase inhibitors (MAOIs) and other drugs that affect neurotransmitter levels. It is important to consult with a healthcare provider before using Periolimel 2.5% E 0.06 G in conjunction with other medications.

Frequently Asked Questions

Periolimel 2.5% E 0.06 G is used for nutritional support in patients who require intravenous administration of L-Tyrosine.

Periolimel 2.5% E 0.06 G is administered intravenously. It is important to follow the manufacturer's guidelines for proper administration.

Common side effects may include nausea and vomiting. Patients should be monitored for any adverse reactions.

L-Tyrosine can interact with certain medications, so it is important to consult with a healthcare provider before using it with other drugs.

Patients with known allergies to L-Tyrosine or any of the ingredients should avoid using this product. Proper storage and preparation guidelines should be followed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.